Drug Profile


Alternative Names: Interleukin-4 - DNAX; Quadrakine; SCH 39400

Latest Information Update: 20 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Nonindustrial sources; Schering-Plough
  • Class Interleukins
  • Mechanism of Action B cell stimulants; Interleukin 1 beta inhibitors; Interleukin 4 receptor agonists; Interleukin 6 receptor antagonists; Interleukin 8 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastrointestinal cancer; Immunodeficiency disorders; Inflammation; Kaposi's sarcoma; Malignant melanoma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Psoriasis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 20 Aug 2009 Discontinued - Clinical-Phase-Unknown for Psoriasis in Netherlands (SC)
  • 26 May 2003 Clinical trials in Psoriasis in Germany (SC)
  • 26 May 2003 Clinical trials in Psoriasis in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top